Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled study

Journal of Pineal Research

Volumn 53, Issue 3, 2012, Pages 238-244

  De Matos Cavalcante, Antonio George ^a   De Bruin, Pedro Felipe Carvalhedo ^a   De Bruin, Veralice Meireles Sales ^a   Nunes, Deuzilane Muniz ^a   Pereira, Eanes Delgado Barros ^a   Cavalcante, Marina Medeiros ^b   Andrade, Geanne Matos ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF FORTALEZA   (Brazil)

Author keywords

chronic obstructive pulmonary disease; exhaled breath condensate; inflammation; interleukin 8; isoprostane; melatonin; oxidative stress

Indexed keywords

8 ISOPROSTANE; FENOTEROL; FORMOTEROL; INTERLEUKIN 8; MELATONIN; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE;

ARTICLE; BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; EXERCISE; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG; LUNG FUNCTION; MALE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTIOXIDANTS; DINOPROST; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HUMANS; LUNG; MALE; MELATONIN; MIDDLE AGED; OXIDATIVE STRESS; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

EID: 84866238034     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2012.00992.x     Document Type: Article

References (55)

1. Celli BR, Macnee W,. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
2. Brusselle GG, Joos GF, Bracke KR,. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015-1026.
3. Barnes PJ, Celli BR,. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
4. Kostikas K, Papatheodorou G, Psathakis K, et al., Oxidative stress in expired breath condensate of patients with COPD. Chest 2003; 124: 1373-1380. (Pubitemid 37290047)
5. Gan WQ, Man SF, Senthilselvan A, et al., Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580. (Pubitemid 38901515)
6. Barnes PJ,. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515-548. (Pubitemid 39658462)
7. Rahman I, Adcock IM,. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-242. (Pubitemid 44914279)
8. Cavalcante AG, De Bruin PF,. The role of oxidative stress in COPD: current concepts and perspectives. J Bras Pneumol 2009; 35: 1227-1237.
9. Kasielski M, Nowak D,. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95: 448-456. (Pubitemid 32621997)
10. De Benedetto F, Aceto A, Dragani B, et al., Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005; 18: 41-47. (Pubitemid 39647752)
11. Decramer M, Rutten-Van Molken M, Dekhuijzen PN, et al., Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560. (Pubitemid 40615404)
12. Reiter RJ, Tan DX, Fuentes-Broto L,. Melatonin: a multitasking molecule. Prog Brain Res 2010; 181: 127-1251.
13. Tan DX, Chen LD, Endocr J, et al., Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
14. Bonnefont-Rousselot D, Collin F, Jore D, et al., Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res 2011; 50: 328-335.
15. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
16. Barlow-Walden LR, Reiter RJ, Abe M, et al., Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
17. De Castro-Silva C, De Bruin VM, Cunha GM, et al., Melatonin improves sleep and reduces nitrite in the exhaled breath condensate in cystic fibrosis - a randomized, double-blind placebo-controlled study. J Pineal Res 2010; 48: 65-71.
18. Chahbouni M, Escames G, Venegas C, et al., Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010; 48: 282-289.
19. Celinski K, Konturek SJ, Konturek PC, et al., Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res 2011; 50: 389-394.
20. Seabra ML, Bignotto M, Pinto LR Jr, et al., Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000; 29: 193-200.
21. Buscemi N, Vandermeer B, Hooton N, et al., Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332: 385-393.
22. Montuschi P, Corradi M, Ciabattoni G, et al., Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216-220. (Pubitemid 29326091)
23. Miller MR, Hankinson J, Brusasco V, et al., Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
24. Camargo LA, Pereira CA,. Dyspnea in COPD: beyond the modified Medical Research Council scale. J Bras Pneumol 2010; 36: 571-578.
25. Troosters T, Gosselink R, Decramer M,. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999; 14: 270-274. (Pubitemid 29461288)
26. Nunes DM, Mota RM, Machado MO, et al., Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res 2008; 41: 926-931.
27. Stege G, Vos PJ, Van Den Elshout FJ, et al., Sleep, hypnotics and chronic obstructive pulmonary disease. Respir Med 2008; 102: 801-814.
28. Nunes DM, Mota RM, De Pontes Neto OL, et al., Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung 2009; 187: 159-163.
29. Reiter RJ, Paredes SD, Manchester LC, et al., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
30. Jou MJ, Peng TI, Hsu LF, et al., Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2 +)-mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res 2010; 48: 20-38.
31. Zhang L, Wei W, Xu J, et al., Inhibitory effect of melatonin on diquat-induced lipid peroxidation in vivo as assessed by the measurement of F2-isoprostanes. J Pineal Res 2006; 40: 326-331.
32. Xu J, Sun S, Wei W, et al., Melatonin reduces mortality and oxidatively mediated hepatic and renal damage due to diquat treatment. J Pineal Res 2007; 42: 166-171. (Pubitemid 46233063)
33. Taketani T, Tamura H, Takasaki A, et al., Protective role of melatonin in progesterone production by human luteal cells. J Pineal Res 2011; 51: 207-213.
34. Manda K, Ueno M, Anzai K,. Melatonin mitigates oxidative damage and apoptosis in mouse cerebellum induced by high-LET 56Fe particle irradiation. J Pineal Res 2008; 44: 189-196. (Pubitemid 351252922)
35. Montilla-Lopez P, Munoz-Agueda MC, Feijoo Lopez M, et al., Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol 2002; 451: 237-243. (Pubitemid 35254026)
36. Sener G, Sehirli AO, Ayanoglu-Dulger G,. Protective effects of melatonin, vitamin E and N-acetylcysteine against acetaminophen toxicity in mice: a comparative study. J Pineal Res 2003; 35: 61-68. (Pubitemid 36819172)
37. Owen CA,. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 373-385, Discussion 394-395. (Pubitemid 41699700)
38. Morrow JD, Roberts LJ,. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002; 166: S25-S30. (Pubitemid 36015933)
39. Halliwell B, Whiteman M,. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004; 142: 231-255. (Pubitemid 38746160)
40. Dalle-Donne I, Rossi R, Colombo R, et al., Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52: 601-623.
41. Horvath I, Hunt J, Barnes PJ, et al., Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26: 523-548. (Pubitemid 41264218)
42. Nishimura K, Izumi T, Tsukino M, et al., Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440. (Pubitemid 34499652)
43. Chhabra SK, Gupta AK, Khuma MZ,. Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease. Ann Thorac Med 2009; 4: 128-132.
44. Makris D, Paraskakis E, Korakas P, et al., Exhaled breath condensate 8-isoprostane, clinical parameters, radiological indices and airway inflammation in COPD. Respiration 2008; 75: 138-144. (Pubitemid 351363866)
45. Taylor-Clark TE, Undem BJ,. Sensing pulmonary oxidative stress by lung vagal afferents. Respir Physiol Neurobiol 2011; 178: 406-413.
46. Stockley RA,. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin 2009; 25: 1235-1245.
47. Wedzicha JA,. Exacerbations: etiology and pathophysiologic mechanisms. Chest 2002; 121: 136S-141S. (Pubitemid 34497331)
48. Kim GD, Lee SE, Kim TH, et al., Melatonin suppresses acrolein-induced IL-8 production in human pulmonary fibroblasts. J Pineal Res 2012; 52: 356-364.
49. Gumral N, Naziroglu M, Ongel K, et al., Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct 2009; 27: 276-283.
50. Pela R, Marchesani F, Agostinelli C, et al., Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53: 262-267. (Pubitemid 28461652)
51. Sethi S, Evans N, Grant BJ, et al., New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471. (Pubitemid 34879333)
52. Tekbas OF, Ogur R, Korkmaz A, et al., Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule. J Pineal Res 2008; 44: 222-226. (Pubitemid 351255501)
53. Ninomiya T, Iwatani N, Tomoda A, et al., Effects of exogenous melatonin on pituitary hormones in humans. Clin Physiol 2001; 21: 292-229.
54. Luboshitzky R, Levi M, Shen-Orr Z, et al., Long-term melatonin administration does not alter pituitary-gonadal hormone secretion in normal men. Hum Reprod 2000; 15: 60-65. (Pubitemid 30035100)
55. Luboshitzky R, Shen-Orr Z, Nave R, et al., Melatonin administration alters semen quality in healthy men. J Androl 2002; 23: 572-578. (Pubitemid 34655092)